Skip to main content
OpenTrials
Completed

NCT Number: NCT05264363

Clinical Validation of the VIPUN GMS as a Gastric Motility Monitoring System

In order to validate that the VIPUN, Gastric Monitoring System (GMS) is a gastric motility monitoring system, we intend to show that the VIPUN GMS can assess motility through pressure measurement similar to high-resolution manometry (HRM).

In addition, the study aims to contribute to the design and development of a position confirmation functionality integrated in the VIPUN Gastric Monitoring System by establishing volume-pressure relations in the stomach and esophagus.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Translational Research Center for Gastrointestinal Disorders - KU Leuven

Leuven, Vlaams-Brabant, 3000, Belgium

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed Informed Consent Form
  • Aged between and including 18 and 65 years
  • In good health on the basis of medical history and anamnesis by the Principal Investigator (or delegate)
  • Agrees to refrain from drug, non-allowed medication, herbal supplement and dietary supplement intake on the day of the study visit
  • Agrees to an overnight fast in advance of the study visit

Exclusion criteria

  • Current or chronic gastrointestinal symptoms
  • Use of any medication that might affect gastric function or visceral sensitivity in the opinion of the PI
  • (Suspected) current use of illicit drugs
  • Psychiatric or neurological illness
  • Any history of gastrointestinal surgery that could influence normal gastric function in the opinion of the PI, including, but not limited to gastrectomy, esophagectomy, duodenotomy, pancreatectomy, bariatric surgery (bypass surgery, gastric banding…), placement of neuromodulator
  • Simultaneous participation in other clinical studies
  • Suspected or confirmed basal skull fracture, mid face trauma or maxillofacial trauma
  • Nasopharyngeal surgery in the last 30 days
  • History of severe coagulation abnormalities
  • Therapeutic or prophylactic anticoagulation
  • Gastrointestinal bleeding
  • Ischemic bowel
  • Peritonitis
  • Deviated nasal septum impeding catheter placement
  • Inability to pass a feeding tube through the nares (e.g. in case of anatomical features, nasal congestion or blockage)
  • Recent (< 30 days) caustic ingestion (due to risk of esophageal rupture)
  • Recent (< 30 days) esophageal varices (active, untreated or recently banded/cauterized)
  • History of esophageal strictures
  • History of gastric varices
  • History of gastric obstruction
  • History of gastrectomy, esophagectomy, duodeno-pancreatectomy, bypass surgery, gastric banding, bariatric balloon, or short bowel syndrome
  • History of gastrostomy
  • Allergy to components of the VIPUN Catheter
  • Pregnancy or breastfeeding
  • Allergy to components of the enteral nutrition
  • Allergy to the available lubricants
  • Allergy to the available local anesthetic
  • Recent infection with SARS-CoV-2 (in the last 2 weeks prior to study visit).

Treatment and study plan

VIPUN Gastric Monitoring System prototype

Device

The Investigational Medical Device (IMD) is used simultaneously with the reference device (solid state high-resolution manometry) to record gastric intraluminal pressure for approximately 2.5 hours.

Other names: VIPUN GMS

Primary outcomes

  1. Duration of gastric contractility on VIPUN GMS

    Time frame: protocol time T=0-120 minutes

    Time the smoothed and baseline-corrected VIPUN GMS pressure exceeds the contraction-threshold.

  2. Duration of gastric contractility on manometry

    Time frame: protocol time T=0-120 minutes

    Time the smoothed and baseline-corrected gastric manometry pressure exceeds the contraction-threshold

Secondary outcomes

  1. VIPUN GMS contraction frequency

    Time frame: protocol time T=0-120 minutes

    Gastric contractions identified visually by a expert gastroenterologists on the VIPUN GMS recording.

  2. Manometry contraction frequency

    Time frame: protocol time T=0-120 minutes

    Gastric contractions identified visually by a expert gastroenterologists on the manometry recording.

  3. Motility Tiled Runner contraction frequency

    Time frame: protocol time T=0-120 minutes

    Motility Tile Runner contractions are gastric contractions identified by the VIPUN Motility Tiled Runner software application.

  4. Hallmarks of normal motility

    Time frame: protocol time T=0-150 minutes

    The presence/absence of hallmarks of normal gastric motility are scored by expert gastroenterologists on the VIPUN GMS pressure recording and on the manometry recording independently.

  5. Duration of MMC phases

    Time frame: protocol time T=0-150 minutes

    The duration of MMC phase III is delineated by expert gastroenterologists on the VIPUN GMS pressure recording and on the manometry recording independently.

  6. Nutrient-induced changes in tonic contractility

    Time frame: protocol time T=0-150 minutes

    Defined as the difference between baseline GMS pressure before and during nutrient administration.

  7. Nutrient-induced changes in phasic contractility

    Time frame: protocol time T=0-150 minutes

    Defined as the difference between the frequency of Motility Tiled Runner contractions before and during nutrient administration.

  8. Volume-pressure relation during stepwise inflation

    Time frame: Prior to protocol time T=0 minutes (=start motility recording).

    The pressure at each volume increment (range 0-135 ml) is recorded during stepwise inflation of the VIPUN GMS Catheter in the esophagus and in the stomach.

Other outcomes

  1. Symptom severity

    Time frame: Throughout the study visit, specifically at baseline, during stepwise inflation (at each volume increment), and during the motility recording (at protocol time T=0, 60, 120 and 150 minutes).

    The severity of epigastric and nasopharyngeal symptoms are surveyed by means of a questionnaire throughout the study visit.

  2. Device safety

    Time frame: Throughout study visit (from the moment the investigational medical device is applied until it is removed).

    All adverse events and device deficiencies are recorded.

Sponsors and collaborators

Lead sponsor

VIPUN Medical

Industry

Registry information

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Mar 3, 2022
Registry last updated
Dec 21, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.